Dementia in Parkinson's disease

Journal of the Neurological Sciences

Volumn 374, Issue , 2017, Pages 26-31

  Hanagasi, Hasmet A ^a   Tufekcioglu, Zeynep ^a   Emre, Murat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cholinesterase inhibitors; Dementia; Dementia with Lewy Bodies; Parkinson's disease

Indexed keywords

BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR;

CLINICAL FEATURE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; HEREDITY; HUMAN; INCIDENCE; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; COMPLICATION; PATHOLOGY;

CHOLINESTERASE INHIBITORS; DEMENTIA; HUMANS; PARKINSON DISEASE;

EID: 85009469650     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2017.01.012     Document Type: Review

References (83)

1. [1] Aarsland, D., Zaccai, J., Brayne, C., A systematic review of prevalence studies of dementia in Parkinson's disease. Mov. Disord. 20:10 (Oct 2005), 1255–1263.
2. [2] Williams-Gray, C.H., Mason, S.L., Evans, J.R., et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J. Neurol. Neurosurg. Psychiatry 84:11 (2013), 1258–1264, 10.1136/jnnp-2013-305277.
3. [3] Santangelo, G., Vitale, C., Picillo, M., Moccia, M., Cuoco, S., Longo, K., et al. Mild Cognitive Impairment in newly diagnosed Parkinson's disease: a longitudinal prospective study. Parkinsonism Relat. Disord. 21:10 (Oct 2015), 1219–1226, 10.1016/j.parkreldis.2015.08.024 (Epub 2015 Aug 21).
4. [4] Pigott, K., Rick, J., Xie, S.X., Hurtig, H., Chen-Plotkin, A., Duda, J.E., et al. Longitudinal study of normal cognition in Parkinson disease. Neurology 85:15 (Oct 13 2015), 1276–1282, 10.1212/WNL.0000000000002001 (Epub 2015 Sep 11).
5. [5] Hely, M.A., Morris, J.G., Reid, W.G., Trafficante, R., Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord. 20:2 (Feb 2005), 190–199 (PubMed PMID: 15551331).
6. [6] Hely, M.A., Reid, W.G., Adena, M.A., Halliday, G.M., Morris, J.G., The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23:6 (Apr 30 2008), 837–844, 10.1002/mds.21956 (PubMed PMID: 18307261).
7. [7] Levy, G., Schupf, N., Tang, M.-X., Cote, L.J., Louis, E.D., Mejia, H., et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann. Neurol. 51:6 (Jun 2002), 722–729.
8. [8] Marion, M.-H., Qurashi, M., Marshall, G., Foster, O., Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson's disease?. J. Neurol. 255:2 (Feb 2008), 192–196.
9. [9] Anang, J.B., Gagnon, J.F., Bertrand, J.A., Romenets, S.R., Latreille, V., Panisset, M., et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 83:14 (Sep 30 2014), 1253–1260, 10.1212/WNL.0000000000000842 (Epub 2014 Aug 29).
10. [10] Williams-Gray, C.H., Evans, J.R., Goris, A., Foltynie, T., Ban, M., Robbins, T.W., et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 132:Pt 11 (Nov 2009), 2958–2969.
11. [11] Lee, S.J., Kim, J.S., Yoo, J.Y., Song, I.U., Kim, B.S., Jung, S.L., et al. Influence of white matter hyperintensities on the cognition of patients with Parkinson disease. Alzheimer Dis. Assoc. Disord. 24:3 (Sep 2010), 227–233.
12. [12] Ham, J.H., Lee, J.J., Sunwoo, M.K., Hong, J.Y., Sohn, Y.H., Lee, P.H., Effect of olfactory impairment and white matter hyperintensities on cognition in Parkinson's disease. Parkinsonism Relat. Disord. 24 (Mar 2016), 95–99, 10.1016/j.parkreldis.2015.12.017 (Epub 2015 Dec 31).
13. [13] Lee, S.J., Lee, D.G., The cross-sectional and longitudinal relationships between white matter hyperintensities and dementia in patients with Parkinson's disease: a retrospective analysis of 132 patients in a single center. Arch. Gerontol. Geriatr. 62 (Jan–Feb 2016), 133–137, 10.1016/j.archger.2015.10.006 (Epub 2015 Oct 26).
14. [14] Kandiah, N., Zainal, N.H., Narasimhalu, K., Chander, R.J., Ng, A., Mak, E., et al. Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease. Parkinsonism Relat. Disord. 20:11 (Nov 2014), 1203–1208, 10.1016/j.parkreldis.2014.08.024 (Epub 2014 Sep 16).
15. [15] Pilotto, A., Turrone, R., Liepelt-Scarfone, I., Bianchi, M., Poli, L., Borroni, B., et al. Vascular risk factors and cognition in Parkinson's disease. J. Alzheimers Dis. 51:2 (2016), 563–570, 10.3233/JAD-150610.
16. [16] Malek, N., Lawton, M.A., Swallow, D.M., Grosset, K.A., Marrinan, S.L., Bajaj, N., et al., PRoBaND Clinical Consortium, Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease. Mov. Disord., Jun 21 2016, 10.1002/mds.26698.
17. [17] Mata, I.F., Leverenz, J.B., Weintraub, D., Trojanowski, J.Q., Hurtig, H.I., Van Deerlin, V.M., et al. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol. 71:11 (Nov 2014), 1405–1412, 10.1001/jamaneurol.2014.1455.
18. [18] Huang, X., Chen, P.C., Poole, C., APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 62:12 (Jun 22 2004), 2198–2202.
19. [19] Goris, A., Williams-Gray, C.H., Clark, G.R., Foltynie, T., Lewis, S.J.G., Brown, J., et al. Tau and alpha-synuclein in susceptibility to, and dementia in Parkinson's disease. Ann. Neurol. 62:2 (Aug 2007), 145–153.
20. [20] Healy, D.G., Abou-Sleiman, P.M., Lees, A.J., Casas, J.P., Quinn, N., Bhatia, K., et al. Tau gene and Parkinson's disease: a case-control study and meta-analysis. J. Neurol. Neurosurg. Psychiatry 75:7 (Jul 2004), 962–965.
21. [21] Winder-Rhodes, S.E., Evans, J.R., Ban, M., Mason, S.L., Williams-Gray, C.H., Foltynie, T., et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 136:Pt 2 (Feb 2013), 392–399, 10.1093/brain/aws318.
22. [22] Zokaei, N., McNeill, A., Proukakis, C., Beavan, M., Jarman, P., Korlipara, P., et al. Visual short-term memory deficits associated with GBA mutation and Parkinson's disease. Brain 137:Pt 8 (Aug 2014), 2303–2311, 10.1093/brain/awu143 (Epub 2014 Jun 11).
23. [23] Davis, M.Y., Johnson, C.O., Leverenz, J.B., Weintraub, D., Trojanowski, J.Q., Chen-Plotkin, A., et al. Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease. JAMA Neurol., Aug 29 2016, 10.1001/jamaneurol.2016.2245.
24. [24] Farrer, M., Kachergus, J., Forno, L., Lincoln, S., Wang, D.-S., Hulihan, M., et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55:2 (Feb 2004), 174–179.
25. [25] Sironi, F., Trotta, L., Antonini, A., Zini, M., Ciccone, R., Della Mina, E., et al. alpha-Synuclein multiplication analysis in Italian familial Parkinson disease. Parkinsonism Relat. Disord. 16:3 (Mar 2010), 228–231.
26. [26] Alcalay, R.N., Caccappolo, E., Mejia-Santana, H., Tang, M.X., Rosado, L., Orbe Reilly, M., et al. Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol. 71:1 (Jan 2014), 62–67, 10.1001/jamaneurol.2013.4498.
27. [27] Petrova, M., Raycheva, M., Traykov, L., Cognitive profile of the earliest stage of dementia in Parkinson's disease. Am. J. Alzheimers Dis. Other Demen. 27:8 (Dec 2012), 614–619, 10.1177/1533317512460562 (Epub 2012 Sep 19).
28. [28] Marras, C., Armstrong, M.J., Meaney, C.A., Fox, S., Rothberg, B., Reginold, W., et al. Measuring mild cognitive impairment in patients with Parkinson's disease. Mov. Disord. 28:5 (May 2013), 626–633, 10.1002/mds.25426 (Epub 2013 Mar 20).
29. [29] Broeders, M., de Bie, R.M., Velseboer, D.C., Speelman, J.D., Muslimovic, D., Schmand, B., Evolution of mild cognitive impairment in Parkinson disease. Neurology 81:4 (Jul 23 2013), 346–352, 10.1212/WNL.0b013e31829c5c86 (Epub 2013 Jun 21).
30. [30] Goldman, J.G., Holden, S., Bernard, B., Ouyang, B., Goetz, C.G., Stebbins, G.T., Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov. Disord. 28:14 (Dec 2013), 1972–1979, 10.1002/mds.25655 (Epub 2013 Oct 9).
31. [31] Pfeiffer, H.C., Løkkegaard, A., Zoetmulder, M., Friberg, L., Werdelin, L., Cognitive impairment in early-stage non-demented Parkinson's disease patients. Acta Neurol. Scand. 129:5 (May 2014), 307–318, 10.1111/ane.12189 (Epub 2013 Oct 11).
32. [32] Yarnall, A.J., Breen, D.P., Duncan, G.W., Khoo, T.K., Coleman, S.Y., Firbank, M.J., et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 82:4 (Jan 28 2014), 308–316, 10.1212/WNL.0000000000000066 (Epub 2013 Dec 20).
33. [33] Stefanova, E., Žiropadja, L., Stojković, T., Stanković, I., Tomić, A., Ječmenica-Lukić, M., et al. Mild cognitive impairment in early Parkinson's disease using the Movement Disorder Society Task Force Criteria: cross-sectional study in Hoehn and Yahr stage 1. Dement. Geriatr. Cogn. Disord. 40:3–4 (2015), 199–209, 10.1159/000433421 (Epub 2015 Jul 28).
34. [34] Johnson, D.K., Langford, Z., Garnier-Villarreal, M., Morris, J.C., Galvin, J.E., Onset of mild cognitive impairment in Parkinson disease. Alzheimer Dis. Assoc. Disord. 30:2 (Apr–Jun 2016), 127–133, 10.1097/WAD.0000000000000088.
35. [35] Noe, E., Marder, K., Bell, K.L., Jacobs, D.M., Manly, J.J., Stern, Y., Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov. Disord. 19:1 (Jan 2004), 60–67 (PubMed PMID: 14743362).
36. [36] Weintraub, D., Moberg, P.J., Culbertson, W.C., Duda, J.E., Stern, M.B., Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn. Behav. Neurol. 17:4 (Dec 2004), 195–200.
37. [37] Mosimann, U.P., Mather, G., Wesnes, K.A., O'Brien, J.T., Burn, D.J., McKeith, I.G., Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 63:11 (Dec 14 2004), 2091–2096.
38. [38] Aarsland, D., Brønnick, K., Ehrt, U., De Deyn, P.P., Tekin, S., Emre, M., et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J. Neurol. Neurosurg. Psychiatry 78:1 (Jan 2007), 36–42.
39. [39] Pagonabarraga, J., Llebaria, G., García-Sánchez, C., Pascual-Sedano, B., Gironell, A., Kulisevsky, J., A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia. Mov. Disord. 23:3 (Feb 15 2008), 443–448.
40. [40] McDonald, C., Newton, J.L., Burn, D.J., Orthostatic hypotension and cognitive impairment in Parkinson's disease: causation or association?. Mov. Disord. 31:7 (Jul 2016), 937–946, 10.1002/mds.26632 (Review. PubMed PMID: 27091624).
41. [41] Allan, L.M., Ballard, C.G., Allen, J., Murray, A., Davidson, A.W., McKeith, I.G., et al. Autonomic dysfunction in dementia. J. Neurol. Neurosurg. Psychiatry 78:7 (Jul 2007), 671–677.
42. [42] Emre, M., What causes mental dysfunction in Parkinson's disease?. Mov. Disord. 18:Suppl. 6 (Sep 2003), S63–S71.
43. [43] Horvath, J., Herrmann, F.R., Burkhard, P.R., Bouras, C., Kövari, E., Neuropathology of dementia in a large cohort of patients with Parkinson's disease. Parkinsonism Relat. Disord. 19:10 (Oct 2013), 864–868 discussion 864 10.1016/j.parkreldis.2013.05.010 (Epub 2013 Jun 6).
44. [44] Irwin, D.J., White, M.T., Toledo, J.B., Xie, S.X., Robinson, J.L., Van Deerlin, V., et al. Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol. 72:4 (Oct 2012), 587–598, 10.1002/ana.23659 (Epub 2012 Oct 4).
45. [45] Schneider, J.A., Arvanitakis, Z., Yu, L., Boyle, P.A., Leurgans, S.E., Bennett, D.A., Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain 135:Pt 10 (Oct 2012), 3005–3014, 10.1093/brain/aws234.
46. [46] Liu, A.K., Chang, R.C., Pearce, R.K., Gentleman, S.M., Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease. Acta Neuropathol. 129:4 (Apr 2015), 527–540, 10.1007/s00401-015-1392-5 (Epub 2015 Jan 30. Review).
47. [47] Jellinger, K.A., Morphological substrates of mental dysfunction in Lewy body disease: an update. J. Neural Transm. Suppl. 59 (2000), 185–212.
48. [48] Jellinger, K.A., Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 14:3 (Jun 1991), 153–197.
49. [49] Apostolova, L.G., Beyer, M., Green, A.E., Hwang, K.S., Morra, J.H., Chou, Y.-Y., et al. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. Mov. Disord. 25:6 (Apr 30 2010), 687–688.
50. [50] Borroni, B., Premi, E., Formenti, A., Turrone, R., Alberici, A., Cottini, E., et al. Structural and functional imaging study in dementia with Lewy bodies and Parkinson's disease dementia. Parkinsonism Relat. Disord. 21:9 (Sep 2015), 1049–1055, 10.1016/j.parkreldis.2015.06.013 (Epub 2015 Jun 16).
51. [51] Seibert, T.M., Murphy, E.A., Kaestner, E.J., Brewer, J.B., Interregional correlations in Parkinson disease and Parkinson-related dementia with resting functional MR imaging. Radiology 263:1 (Apr 2012), 226–234.
52. [52] Peraza, L.R., Colloby, S.J., Firbank, M.J., Greasy, G.S., McKeith, I.G., Kaiser, M., et al. Resting state in Parkinson's disease dementia and dementia with Lewy bodies: commonalities and differences. Int. J. Geriatr. Psychiatry 30:11 (Nov 2015), 1135–1146, 10.1002/gps.4342 (Epub 2015 Aug 13).
53. [53] Duncan, G.W., Firbank, M.J., Yarnall, A.J., Khoo, T.K., Brooks, D.J., Barker, R.A., et al. Gray and white matter imaging: a biomarker for cognitive impairment in early Parkinson's disease?. Mov. Disord. 31:1 (Jan 2016), 103–110, 10.1002/mds.26312 (PubMed PMID: 26202802).
54. [54] Pavese, N., PET studies in Parkinson's disease motor and cognitive dysfunction. Parkinsonism Relat. Disord. 18:Suppl. 1 (Jan 2012), S96–S99.
55. [55] Hilker, R., Thomas, A.V., Klein, J.C., Weisenbach, S., Kalbe, E., Burghaus, L., et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65:11 (Dec 13 2005), 1716–1722.
56. [56] Maetzler, W., Reimold, M., Liepelt, I., Solbach, C., Leyhe, T., Schweitzer, K., et al. [11C]PIB binding in Parkinson's disease dementia. NeuroImage 39:3 (Feb 1 2008), 1027–1033.
57. [57] Edison, P., Rowe, C.C., Rinne, J.O., Ng, S., Ahmed, I., Kemppainen, N., et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J. Neurol. Neurosurg. Psychiatry 79:12 (Dec 2008), 1331–1338.
58. [58] Stav, A.L., Aarsland, D., Johansen, K.K., Hessen, E., Auning, E., Fladby, T., Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. Parkinsonism Relat. Disord. 21:7 (Jul 2015), 758–764, 10.1016/j.parkreldis.2015.04.027 (Epub 2015 May 2).
59. [59] Bäckström, D.C., Eriksson Domellöf, M., Linder, J., Olsson, B., Öhrfelt, A., Trupp, M., et al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. 72:10 (Oct 2015), 1175–1182, 10.1001/jamaneurol.2015.1449.
60. [60] Skillbäck, T., Farahmand, B.Y., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., et al. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Brain 138:Pt 9 (Sep 2015), 2716–2731, 10.1093/brain/awv181 (Epub 2015 Jun 30).
61. [61] Stewart, T., Liu, C., Ginghina, C., Cain, K.C., Auinger, P., Cholerton, B., Shi, M., Zhang, J., Parkinson Study Group DATATOP Investigators, Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am. J. Pathol. 184:4 (Apr 2014), 966–975, 10.1016/j.ajpath.2013.12.007 (Epub 2014 Mar 11. PubMed PMID: 24625392; PubMed Central PMCID: PMC3969999).
62. [62] Latreille, V., Carrier, J., Gaudet-Fex, B., Rodrigues-Brazète, J., Panisset, M., Chouinard, S., et al. Electroencephalographic prodromal markers of dementia across conscious states in Parkinson's disease. Brain 139:Pt 4 (Apr 2016), 1189–1199, 10.1093/brain/aww018 (Epub 2016 Feb 16).
63. [63] Emre, M., Aarsland, D., Brown, R., Burn, D.J., Duyckaerts, C., Mizuno, Y., et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord. 22:12 (Sep 15 2007), 1689–1707 (quiz 1837).
64. [64] Dubois, B., Burn, D., Goetz, C., Aarsland, D., Brown, R.G., Broe, G.A., et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov. Disord. 22:16 (Dec 2007), 2314–2324.
65. [65] Litvan, I., Goldman, J.G., Tröster, A.I., Schmand, B.A., Weintraub, D., Petersen, R.C., et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 27:3 (Mar 2012), 349–356.
66. [66] McKeith, I.G., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J. Alzheimers Dis. 9:Suppl. 3 (2006), 417–423.
67. [67] Aarsland, D., Londos, E., Ballard, C., Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity. Int. Psychogeriatr. 21:2 (Apr 2009), 216–219.
68. [68] Lippa, C.F., Duda, J.E., Grossman, M., Hurtig, H.I., Aarsland, D., Boeve, B.F., et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68:11 (Mar 13 2007), 812–819.
69. [69] McKeith, I.G., Mosimann, U.P., Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat. Disord. 10:Suppl. 1 (May 2004), S15–S18.
70. [70] McKeith, I., Dementia with Lewy bodies and Parkinson's disease with dementia: where two worlds collide. Pract. Neurol. 7:6 (Nov 2007), 374–382.
71. [71] Hepp, D.H., Vergoossen, D.L., Huisman, E., Lemstra, A.W., Netherlands Brain Bank, Berendse, H.W., et al. Distribution and load of amyloid-β pathology in Parkinson disease and dementia with Lewy bodies. J. Neuropathol. Exp. Neurol., Aug 11 2016 (pii: nlw070).
72. [72] Donaghy, P., Thomas, A.J., O'Brien, J.T., Amiloid PET imaging in Lewy body disorders. Am. J. Geriatr. Psychiatry 23:1 (Jan 2015), 23–37, 10.1016/j.jagp.2013.03.001 (Epub 2013 Jul 3).
73. [73] Beyer, M.K., Larsen, J.P., Aarsland, D., Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 69:8 (Aug 21 2007), 747–754 (PubMed PMID: 17709706).
74. [74] McKeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O'Brien, J.T., Feldman, H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:12 (Dec 27 2005), 1863–1872.
75. [75] Mamikonyan, E., Xie, S.X., Melvin, E., Weintraub, D., Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov. Disord. 30:7 (Jun 2015), 912–918, 10.1002/mds.26236 (Epub 2015 Apr 25).
76. [76] Grace, J., Amick, M.M., Friedman, J.H., A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J. Neurol. Neurosurg. Psychiatry 80:1 (Jan 2009), 18–23.
77. [77] Emre, M., Aarsland, D., Albanese, A., Byrne, E.J., Deuschl, G., De Deyn, P.P., et al. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351:24 (Dec 9 2004), 2509–2518.
78. [78] Poewe, W., Wolters, E., Emre, M., Onofrj, M., Hsu, C., Tekin, S., et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov. Disord. 21:4 (Apr 2006), 456–461.
79. [79] Wesnes, K.A., McKeith, I., Edgar, C., Emre, M., Lane, R., Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 65:10 (Nov 22 2005), 1654–1656.
80. [80] Wang, H.F., Yu, J.T., Tang, S.W., Jiang, T., Tan, C.C., Meng, X.F., et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J. Neurol. Neurosurg. Psychiatry 86:2 (Feb 2015), 135–143, 10.1136/jnnp-2014-307659 (Epub 2014 May 14. Review).
81. [81] Aarsland, D., Ballard, C., Walker, Z., Bostrom, F., Alves, G., Kossakowski, K., et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 8:7 (Jul 2009), 613–618.
82. [82] Emre, M., Tsolaki, M., Bonuccelli, U., Destée, A., Tolosa, E., Kutzelnigg, A., et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9:10 (Oct 2010), 969–977.
83. [83] Hughes, A.J., Daniel, S.E., Kilford, L., Lees, A.J., Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55:3 (Mar 1992), 181–184 (PubMed PMID: 1564476; PubMed Central PMCID: PMC1014720).